Clinical Trials Logo

Clinical Trial Summary

The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04733833
Study type Interventional
Source Vascular Biogenics Ltd. operating as VBL Therapeutics
Contact
Status Completed
Phase Phase 2
Start date January 26, 2021
Completion date October 25, 2022

See also
  Status Clinical Trial Phase
Completed NCT05175833 - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19 Phase 2
Recruiting NCT05256511 - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Completed NCT04866082 - Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
Active, not recruiting NCT04918901 - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting NCT05233605 - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Not yet recruiting NCT04613986 - Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19 N/A
Recruiting NCT05447013 - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients Phase 1/Phase 2
Recruiting NCT04712344 - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) Phase 2
Terminated NCT04713176 - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients Phase 3
Recruiting NCT04648410 - Corticosteroids in Severe COVID-19(ASAP-C Study)
Enrolling by invitation NCT06235866 - Risk Identification of Long-term Complications
Recruiting NCT05254990 - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Phase 3
Completed NCT05596617 - Safety and Efficacy of Medications COVID-19 N/A